Stock Events

Stock Events

Brii Biosciences Limited 

€0.15
0
+€0+0.68% Friday 19:16

Statistics

Day High
-
Day Low
-
52W High
0.26
52W Low
0.14
Volume
-
Avg. Volume
65
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MarExpected
Q4 2025
-0.01
0.33
0.66
0.99
Expected EPS
-0.007409416655999999
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7SS.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is a major player in the development of antiviral drugs, directly competing with Brii Biosciences in the infectious disease market.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals focuses on serious diseases, including viral infections, which overlaps with Brii Biosciences' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals competes in the biopharmaceutical field targeting infectious diseases, similar to Brii Biosciences.
Moderna
MRNA
Mkt Cap20.21B
Moderna is known for its mRNA technology used in vaccines, competing in the infectious disease space where Brii Biosciences is also active.
BioNTech
BNTX
Mkt Cap24.15B
BioNTech competes with Brii Biosciences in the development of treatments and vaccines for infectious diseases.
Arbutus Biopharma
ABUS
Mkt Cap811.23M
Arbutus Biopharma is involved in antiviral drug development, making it a direct competitor in Brii Biosciences' core market.
Inovio Pharmaceuticals
INO
Mkt Cap86.49M
Inovio Pharmaceuticals focuses on DNA medicines including vaccines for infectious diseases, aligning as a competitor to Brii Biosciences.
Novavax
NVAX
Mkt Cap1.32B
Novavax is involved in the development of vaccines for infectious diseases, directly competing with Brii Biosciences.

About

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Show more...
CEO
Dr. Zhi Hong Ph.D.
Employees
123
Country
Hong Kong
ISIN
KYG1645A1094

Listings

STU
DE
7SS.STU
HK
HK
2137.HK
MU
DE
7SS.MU
F
DE
7SS.F

0 Comments

Share your thoughts

FAQ

What is Brii Biosciences Limited stock price today?▼
The current price of 7SS.STU is €0.15 EUR — it has increased by +0.68% in the past 24 hours. Watch Brii Biosciences Limited stock price performance more closely on the chart.
What is Brii Biosciences Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Brii Biosciences Limited stocks are traded under the ticker 7SS.STU.
Is Brii Biosciences Limited stock price growing?▼
7SS.STU stock has fallen by -0.67% compared to the previous week, the month change is a -2.63% fall, over the last year Brii Biosciences Limited has showed a -25.63% decrease.
When is the next Brii Biosciences Limited earnings date?▼
Brii Biosciences Limited is going to release the next earnings report on August 20, 2026.
How many employees does Brii Biosciences Limited have?▼
As of April 15, 2026, the company has 123 employees.
In which sector is Brii Biosciences Limited located?▼
Brii Biosciences Limited operates in the Health & Wellness sector.
When did Brii Biosciences Limited complete a stock split?▼
Brii Biosciences Limited has not had any recent stock splits.
Where is Brii Biosciences Limited headquartered?▼
Brii Biosciences Limited is headquartered in Beijing, Hong Kong.